Precigen (PGEN) Gross Profit (2013 - 2026)
Precigen's (PGEN) quarterly Gross Profit came in at $52.2 million in Q2 2026, up 22207.2% year-over-year from N/an in Q2 2025, and up 152.13% quarter-over-quarter from $20.7 million in Q1 2026.
Analysis
Precigen (PGEN) Gross Profit (2013 - 2026) Analysis & Trends
Precigen (PGEN) has reported Gross Profit for 14 consecutive years, with $52.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Profit rose 22207.2% year-over-year to $52.2 million in Q2 2026; TTM through Jun 2026 was $77.7 million, a 259173.33% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 1521.35% from the prior year.
- Gross Profit was $52.2 million for Q2 2026 at Precigen, up from $20.7 million in the prior quarter.
- Over five years, Gross Profit peaked at $52.2 million in Q2 2026 and troughed at -$297000.0 in Q2 2024.
- A 5-year average of $5.4 million and a median of $282500.0 in 2023 frame the typical range for Gross Profit.
- Across the five-year window, Gross Profit tumbled 524.29% in 2024 and surged 22207.2% in 2026, its largest moves.
- Over 5 years, Gross Profit stood at $506000.0 in 2022, then tumbled by 125.69% to -$130000.0 in 2023, then soared by 116.15% to $21000.0 in 2024, then soared by 14038.1% to $3.0 million in 2025, then soared by 1657.26% to $52.2 million in 2026.
- The last three Gross Profit figures came in at $52.2 million (Q2 2026), $20.7 million (Q1 2026), and $3.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn |
| 10 | Taysha Gene Therapies | 1.82 Bn | 1.82 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.17 Mn |
| Mar 31, 2026 | 20.69 Mn |
| Dec 31, 2025 | 2.97 Mn |
| Sep 30, 2025 | 1.89 Mn |
| Jun 30, 2025 | -236,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | -56,000.00 |
| Jun 30, 2024 | -297,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | -130,000.00 |
| Sep 30, 2023 | -158,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Mar 31, 2023 | 324,000.00 |
| Dec 31, 2022 | 506,000.00 |
| Sep 30, 2022 | 15.15 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 3.82 Mn |
| Dec 31, 2021 | 797,000.00 |
| Sep 30, 2021 | 2.36 Mn |